+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Advanced Pancreatic Cancer Drug Pipeline Analysis 2025- Product Image
Advanced Pancreatic Cancer Drug Pipeline Analysis 2025- Product Image
New

Advanced Pancreatic Cancer Drug Pipeline Analysis 2025

  • PDF Icon

    Drug Pipelines

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102864
Description Jump to:
The average lifetime risk of pancreatic cancer is reported to be around 1 in 60 in women and 1 in 56 in men. In the United States, nearly 3% of cancers are pancreatic cancer and are responsible for approximately 7% of all cancer deaths. Advanced pancreatic cancer is usually stage III or IV pancreatic cancer. It occurs when the cancer spreads beyond the pancreas to the other parts of the body and can't be removed by surgery. Current therapies offer only modest survival benefits and are associated with significant toxicity. Thus, there is a critical need for safe and effective targeted therapies and immunotherapies that can combat the aggressive nature of this disease.

Report Coverage

The Advanced Pancreatic Cancer Drug Pipeline Insight Report by the publisher gives comprehensive insights into advanced pancreatic cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced pancreatic cancer. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The advanced pancreatic cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from advanced pancreatic cancer.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to advanced pancreatic cancer.

Advanced Pancreatic Cancer Drug Pipeline Outlook

Advanced pancreatic cancer spreads extensively within the pancreas (locally advanced) or to other parts of the body (metastatic pancreatic cancer). Pancreatic cancer is often diagnosed at an advanced stage as the symptoms are not evident in its early stages. Common symptoms include unexplained weight loss, abdominal pain, vomiting, jaundice, and digestive problems, among others.

Advanced pancreatic cancer is a challenging condition to treat owing to its late diagnosis, aggressive progression, and resistance to standard therapies. Moreover, complex tumor biology makes it difficult for drugs to penetrate tumors effectively. The rising focus on new biomarker research and mRNA-based vaccines is anticipated to improve patient outcomes in the coming years. Additionally, the growing advancements in immunotherapy and robust regulatory support are poised to positively impact the drug pipeline landscape for advanced pancreatic cancer in the near future.

Advanced Pancreatic Cancer - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of advanced pancreatic cancer drugs based on several segmentations including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Small Molecules
  • Monoclonal Antibodies
  • Gene Therapies
  • Oncolytic Viruses
  • Immunotherapies

By Route of Administration

  • Oral
  • Parenteral
  • Others

Advanced Pancreatic Cancer - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase I covers a major share of the total clinical trials for advanced pancreatic cancer.

Advanced Pancreatic Cancer - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the advanced pancreatic cancer pipeline analysis include small molecules, monoclonal antibodies, gene therapies, oncolytic viruses, and immunotherapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for advanced pancreatic cancer.

Advanced Pancreatic Cancer Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the advanced pancreatic cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in advanced pancreatic cancer clinical trials:
  • HCW Biologics
  • Helix BioPharma Corporation
  • Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Shouyao Holdings (Beijing) Co., LTD.

Advanced Pancreatic Cancer- Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: Minnelide

Sponsored by the National Cancer Institute (NCI), the primary objective of this Phase II single cohort clinical trial with one arm is to evaluate the antitumor activity of the drug candidate minnelide in an estimated 55 adults aged 18 and older with advanced refractory adenosquamous carcinoma of the pancreas (ASCP).

Drug: HCW9218

HCW Biologics is conducting a Phase Ib/II clinical trial aimed at investigating the safety and efficacy of HCW9218 for the treatment of advanced pancreatic cancer. The interventional study has enrolled about 60 subjects and is expected to be completed by February 2025.

Reasons To Buy This Report

The Advanced Pancreatic Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for advanced pancreatic cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within advanced pancreatic cancer pipeline insights.

Key Questions Answered in the Advanced Pancreatic Cancer - Pipeline Insight Report

  • What is the current landscape of advanced pancreatic cancer pipeline drugs?
  • How many companies are developing advanced pancreatic cancer drugs?
  • How many phase III and phase IV drugs are currently present in advanced pancreatic cancer pipeline drugs?
  • Which companies/institutions are leading the advanced pancreatic cancer drug development?
  • What is the efficacy and safety profile of advanced pancreatic cancer pipeline drugs?
  • What are the opportunities and challenges present in the advanced pancreatic cancer drug pipeline landscape?
  • Which company is conducting major trials for advanced pancreatic cancer drugs?
  • What geographies are covered for advanced pancreatic cancer clinical trials?
  • What are emerging trends in advanced pancreatic cancer clinical trials?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Advanced Pancreatic Cancer
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Advanced Pancreatic Cancer
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Advanced Pancreatic Cancer: Epidemiology Snapshot
5.1 Advanced Pancreatic Cancer Incidence by Key Markets
5.2 Advanced Pancreatic Cancer - Patients Seeking Treatment in Key Markets
6 Advanced Pancreatic Cancer: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Advanced Pancreatic Cancer: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Advanced Pancreatic Cancer, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Advanced Pancreatic Cancer Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Advanced Pancreatic Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Docetaxel for Injection (Albumin bound)
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: QingyiHuaji optimized formula
10.2.3 Drug: Innohep, Drug: Chemotherapy: Gemcitabine + Nab-Paclitaxel
10.2.4 Other Drugs
11 Advanced Pancreatic Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Minnelide
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: HCW9218
11.2.3 Other Drugs
12 Advanced Pancreatic Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: Biological: L-DOS47, Drug: Doxorubicin
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Drug: CT-707, Drug: Toripalimab, Drug: Gemcitabine
12.2.3 Other Drugs
13 Advanced Pancreatic Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Advanced Pancreatic Cancer, Key Drug Pipeline Companies
14.1 HCW Biologics
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Helix BioPharma Corporation
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Jiangsu Healthy Life Innovation Medical Technology Co., Ltd.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 AstraZeneca
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Bristol-Myers Squibb
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Eli Lilly and Company
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Shouyao Holdings (Beijing) Co., LTD.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products

Related Topics

Related Products

Pancreatic Cancer Drug Pipeline Analysis Report 2025 - Product Image

Pancreatic Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Pancreatic Cancer Pipeline Analysis Report - Product Image

Pancreatic Cancer Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Advanced Pancreatic Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Advanced Pancreatic Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 138 Pages
  • Global
From
Pancreatic Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Pancreatic Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 129 Pages
  • Global
From
Advanced Pancreatic Cancer - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Advanced Pancreatic Cancer - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.